moneyheap
GEHC · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is GE HealthCare Technologies Inc. Common Stock (GEHC) stock moving?
GEHC rose from about $71 to $75.82 on Oct 28 (+6.6% on 9.6M shares) after a Q3 beat and a raised full-year guidance. The stock kept climbing, closing at $85.81 on Nov 4 (+6.4%, 9.6M shares) with an intraday high of $87.56, then eased to $83.65 on Nov 10 on falling volume (about 3.0M). Analysts followed with higher targets: RBC $90, Barclays $95, BTIG $83, UBS $80 (Neutral), and Citigroup $79 (Neutral). The current price sits near the lower-middle of that range, so most of the upside to the higher targets depends on continued execution. Management said most Q4 revenue is already backed by orders in hand. Risks include a product hold that will mute Q4 PCS growth, a contrast media market that is at capacity, Section 232 tariffs described as the biggest 2027 uncertainty, and the planned departure of the Chief Science and Technology Officer on Dec 31, 2026. Recent product launches, the Laza Medical investment, and hospital installations support the growth story, but none of these items is a financial catalyst on its own.
News behind the analysis
- GE HealthCare Lifts Forecasts on Healthy Hospital SpendingGE HealthCare beat Q3 Wall Street estimates on strong imaging and diagnostics sales and raised its full-year earnings guidance.
- RBC Capital Maintains Outperform on GE HealthCare Techs, Raises Price Target to $90RBC kept its Outperform rating and raised its price target to $90 after the Q3 results.
- Barclays Maintains Overweight on GE HealthCare Techs, Raises Price Target to $95Barclays raised its price target from $85 to $95 and kept its positive rating after the quarter.
- Citigroup Maintains Neutral on GE HealthCare Techs, Raises Price Target to $79Citigroup kept a Neutral rating and lifted its price target to $79 following the results.
- UBS Adjusts Price Target on GE HealthCare Technologies to $80UBS raised its price target from $73 to $80 while maintaining a Neutral rating.
- GE HealthCare Chief Science and Technology Officer Taha Kass-Hout to ResignChief Science and Technology Officer Taha Kass-Hout will resign effective December 31, 2026, according to an 8-K filing.
- GE HealthCare Leads $160 Million Series B Financing for Laza MedicalGE HealthCare led a Series B round of up to $160 million for Laza Medical, which develops AI-powered robotic imaging for cardiac procedures.
- Tampa General Hospital Installs GE HealthCare Allia Moveo SystemTampa General Hospital integrated GE HealthCare's Allia Moveo image-guided therapy system into its clinical hybrid operating room.
- GE HealthCare Announces Intent to Establish MAGNUS Neuro AllianceGE HealthCare announced plans for a collaborative research network focused on neuroscience imaging using ultra high-gradient 3.0T MR systems.
- GE HealthCare Introduces Allia Celeo Imaging SystemGE HealthCare launched Allia Celeo, a ceiling-mounted image-guided system for cardiac and minimally invasive procedures.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare is a Chicago-based maker of medical imaging machines, ultrasound systems, patient monitoring equipment and the drugs injected to make scans clearer. General Electric spun it off in early 2023. It is one of the three biggest makers of imaging equipment in the world, and its newer products include a photon-counting CT scanner.
How it makes money
It sells imaging equipment such as CT, MRI, X-ray and molecular imaging scanners, along with ultrasound systems, patient monitors and anesthesia devices (Patient Care Solutions). It also sells contrast agents and radiotracers used in scans (Pharmaceutical Diagnostics). Imaging is the largest segment. Service contracts and software on its large installed base of machines bring in recurring revenue. Total revenue is roughly $21–22 billion a year, at about $5.5 billion per quarter in 2026, and the order backlog is about $24 billion. The company has said it is reviewing strategic options for the Patient Care Solutions unit.
What usually moves GEHC
- Hospital capital-equipment spending and orders backlog
- Tariffs and input costs like memory chips and freight
- China healthcare demand and policy
- New product adoption (photon-counting CT, MRI, AI tools)
- Contrast-agent supply and Pharmaceutical Diagnostics growth